Bluejay Diagnostics H1 2023 net loss $5.4M; cash down to $5.1M; FDA meeting on IL-6 test

Bluejay Diagnostics, Inc.

2023-Q2 EPS reported -$5.24 vs consensus -$2448.00 ▲ beat (+99.8%)

Net loss $5.4M ($5.24/sh) vs $4.0M ($2.00/sh) in H1 2022; no revenue reported.
Cash and equivalents fell to $5.1M from $10.1M at Dec 31, 2022; company expects to raise capital near-term.
R&D expense doubled to $3.0M, driven by clinical trial costs for Symphony IL-6 sepsis test.
FDA pre-submission meeting on Aug 11, 2023 confirmed 510(k) pathway; company targets submission in H1 2024.
Sales and marketing expense $302K vs $135K in prior period as company builds commercial infrastructure.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bluejay Diagnostics, Inc. reported the six months ended June 30, 2023 results: net income $5.4 million, EPS $5.24 per share.

Period: the six months ended June 30, 2023
Net income: $5.4 million
EPS: $5.24 per share
Result: reported results

Exact text from the filing

The net loss for the six months ended June 30, 2023 was $5.4 million, or $5.24 per share

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-067990

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.